|
In November 2023, Serum Institute has announced to start Phase I & II trials of dengue vaccine in India.
In October 2023, WHO approves world’s 2nd malaria vaccine by Oxford-Serum Institute.
In August 2023, Serum Institute of India CEO, Mr. Adar Poonawalla received the ‘Udyog Mitra’ award from the Government of Maharashtra.
In July 2023, MenFive®, the first conjugate vaccine to protect against the five predominant causes of meningococcal meningitis in Africa, has been prequalified by the World Health Organization (WHO).
In July 2023, UK Minister Mr. George Freeman visits Serum Institute of India.
In May 2023, the International Society for Pharmaceutical Engineering (ISPE) awards Serum Institute of India, the 2023 Facility of the Year Category Award for Supply Chain and Social Impact.
In April 2023, Serum Institute restarts manufacturing of Covishield vaccine as Covid cases surge.
In April 2023, Serum Institute launches country’s first HPV vaccine, ‘CERVAVAC’. It has been jointly created by the Serum Institute of India and the Department of Biotechnology.
In April 2023, The University of Oxford-developed and Serum Institute of India (SII) manufactured and scaled up R21/Matrix-M malaria vaccine, leveraging Novavax’s adjuvant technology, has been licensed for use in Ghana by the country’s Food and Drugs Authority (FDA).
In April 2023, Serum Institute of Life Sciences announced to double up its investment in Biocon's unit to US$ 300 million. With this, Biocon's unit will also get access to SILS' 100 million vaccine doses annually.
In February 2023, Serum Institute of India announces centre of excellence in Hyderabad to tackle future pandemics.
In January 2023, Serum Institute of India launched the first made-in-India qHPV vaccine 'CERVAVAC'.
In January 2023, Serum Institute of India CEO Adar Poonawalla received ‘Dr. Patangrao Kadam Memorial Award’.
|
